Physician profile
Jacob V Johnson
NPI 1851673008
$5,154.87
in general payments reported to CMS, 2019-2025
28 companies · $1,129 in 2025
The $1,129 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $243 · 2020: $223 · 2021: $617 · 2022: $754 · 2023: $986 · 2024: $1,202 · 2025: $1,129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,301 · Education: $15.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,301.42 |
| Education | $15.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $902.00 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $696.88 | 2021-2025 | |
| Lilly USA, LLC | $435.70 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $347.16 | 2019-2025 | Repatha, Otezla, Evenity |
| Merck Sharp & Dohme LLC | $322.00 | 2020-2025 | Verquvo, Januvia, Belsomra |
| Pfizer INC. | $308.89 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $295.79 | 2022-2025 | Rexulti, Abilify Maintena |
| Lundbeck LLC | $258.66 | 2022-2025 | Rexulti |
| Glaxosmithkline, LLC. | $205.67 | 2019-2025 | Trelegy Ellipta |
| Corium, LLC | $197.78 | 2022-2024 | Azstarys |
| Novo Nordisk INC | $181.39 | 2019-2025 | Ozempic, Rybelsus |
| Supernus Pharmaceuticals, INC. | $115.53 | 2021-2023 | Qelbree |
| Inspire Medical Systems, INC. | $107.99 | 2024 | Inspire |
| Ironshore Pharmaceuticals INC. | $87.96 | 2024 | |
| Novartis Pharmaceuticals Corporation | $85.73 | 2021-2023 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $82.76 | 2019 | |
| Sunovion Pharmaceuticals INC. | $80.20 | 2022 | |
| Eisai INC. | $63.81 | 2020-2022 | |
| Xeris Pharmaceuticals, INC. | $62.89 | 2022-2023 | Gvoke Hypopen |
| Amarin Pharma, INC. | $53.89 | 2020-2021 | |
| Mylan Specialty L.P. | $45.22 | 2024 | Yupelri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $41.22 | 2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $38.78 | 2022-2024 | Eliquis |
| Collegium Pharmaceutical, INC. | $35.53 | 2025 | Jornay Pm |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.25 | 2021-2024 | Jardiance |
| Viatris Specialty LLC | $25.66 | 2025 | Yupelri |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $24.18 | 2023 | Aplenzin |
| Dexcom, INC. | $23.35 | 2025 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.